Hong Kong Science and Technology Parks Corporation (HKSTP), in collaboration with InvestHK, led 16 prominent life and health technology companies to BIO 2025, the world’s largest biotechnology event, held in Boston, USA, recently.
This year marks the first time HKSTP joined forces with Hong Kong’s two leading medical faculties – the LKS Faculty of Medicine at The University of Hong Kong (HKU) and the Faculty of Medicine at The Chinese University of Hong Kong (CUHK) – to form a delegation, showcasing Hong Kong’s cutting-edge research capabilities and innovation potential in life sciences and health technologies. The initiative further strengthens Hong Kong’s position as a world-class biotech innovation hub.
The HKSTP Pavilion highlighted the groundbreaking technologies and products of its park companies, featuring innovative solutions across diverse fields such as novel drug development, diagnostic technologies, and medical innovation.
Among the 16 participating companies, they were the members of HKSTP’s incubation programmes including Incu-Bio and ELITE Programme, cutting-edge work from the InnoHK research centers, and other outstanding biotech companies.
During BIO 2025, HKSTP and its park companies made significant strides in fostering cross-border innovation ecosystems and exploring new market opportunities.
“We are thrilled to partner with two leading medical schools for the first time at BIO 2025, demonstrating Hong Kong’s breakthroughs and innovation in life and health technology.
“This delegation not only deepens collaboration between Hong Kong and top global research institutions but also highlights our unique advantages as a core I&T hub in the Greater Bay Area.
“With strong policy and funding support from the HKSAR government, Hong Kong will further serve as a bridge connecting Mainland China and global tech partnerships, solidifying its leadership in life sciences innovation,” said Albert Wong, the CEO of HKSTP.